Advances in high throughput and high content (HT/HC) methods such as those used in the fields of toxicogenomics, bioinformatics, and computational toxicology have the potential to improve both the efficiency and effectiveness of toxicity evaluations and risk assessments. However, prior to use, scientific confidence in these methods should be formally established. Traditional validation approaches that define relevance, reliability, sensitivity and specificity may not be readily applicable. HT/HC methods are not exact replacements for in vivo testing, and although run individually, these assays are likely to be used as a group or battery for decision making and use robotics, which may be unique in each laboratory setting. Building on the frameworks developed in the 2010 Institute of Medicine Report on Biomarkers and the OECD 2007 Report on (Q)SAR Validation, we present constructs that can be adapted to address the validation challenges of HT/HC methods. These are flexible, transparent, and require explicit specification of context and purpose of use such that scientific confidence (validation) can be defined to meet different regulatory applications. Using these constructs, we discuss how anchoring the assays and their prediction models to Adverse Outcome Pathways (AOPs) could facilitate the interpretation of results and support scientifically defensible fit-for-purpose applications.
Introduction
In 2007, the National Research Council released a report entitled Toxicity Testing in the 21st Century: A Vision and A Strategy (TT21C) (NRC, 2007) . The ''Strategy'' in the title refers to the path forward for increasing the use of in vitro high throughput and high content (HT/HC) assays and computational methods in lieu of animal bioassays for safety evaluations, and, should animal testing be required, the approach would indicate the types of studies and endpoints for which in vivo tests are absolutely needed. This paper and the continuing effort to support TT21C is a response to: (1) the advances in understanding the molecular and cellular events responsible for toxicity; (2) the desire to refine, reduce and replace the use of animals in regulatory toxicity testing; and (3) the desire to provide more complete toxicity evaluations for the large number of chemicals in commercial use-an effort that would be practically impossible to achieve using traditional animal testing methods.
In vitro and computational approaches have the potential to improve and inform science-based health assessments for a broad range of chemicals. A successful transition is dependent on use of assays and prediction models for identifying relevant human health outcomes, with a defined degree of confidence. Initially for prioritization and screening of chemicals and, potentially in the future, for hazard prediction, the evaluation will include comparisons to the current animal testing framework and the context for predictive use of these traditional in vivo data. Thus, in addition to research to develop and establish scientific confidence in specific HT/HC methods, a transformation in the testing and evaluation framework itself is needed to assure integration and appropriate use of these new and emerging data for decision making. Integrated testing is envisioned to replace the traditional use of a sequential toxicity testing battery with an evaluation system that takes into account data and information from a variety of sources, including mode of action (MOA), biological profiling using in silico and in vitro methods, and exposure information as well. In this manner, knowledge gained from biological profiling can be used for initial hazard characterization, and any testing in animal models will be comprised of specific studies needed to characterize potential hazards and risks with an adequate degree of scientific certainty.
Confidence in biological profiling methods is key to their application. Thus, there must be an adequate understanding of the validity of these methods and prediction models-the relevance, reliability, sensitivity, and specificity of the assays. The associated computational profiling methods need to be established so that regulatory agencies, the regulated community, and the public can be assured that the use of this knowledge for decision making is scientifically sound.
While there are significant challenges in establishing scientific confidence in new HT/HC methods, many of the elements of traditional validation process (NIEHS, 1997) can still be used. These include: a specific description of the scientific and regulatory rationales and the specific purpose of the method (how the results will be used in decision making); the relationship of the test endpoint(s) to the biologic effect of interest; a detailed protocol for the test system (including materials, methods of measurement and data analysis procedures); structural/physical-chemical domains of applicability; criteria for data interpretation (the prediction model); description of the known limitations of the method; and standards and procedures to be followed to ascertain the method is properly performing (e.g., positive and negative standards to be included in each run).
However, two key elements of the traditional test method validation process can be lacking in certain HT/HC methods. When HT/ HC test methods and batteries, such as those which utilize proprietary methods or one-of-a-kind robotic systems, traditional interlaboratory validation is not achievable, and thus reproducibility of results cannot be independently verified. Furthermore, for many proprietary methods, the data used to develop the prediction models are also proprietary and are not publicly available-this means the traditional approach for independent scientific peer review of prediction models cannot be employed. Validation of HT/HC methods is also impacted by the rapid pace at which new methods are being developed and refined, and the desire to use the newest methods as soon as practically possible. However, these limitations do not negate the need for addressing these elements of validation/ evaluation so as to garner the required scientific confidence in the performance of these test methods and prediction models. These elements cannot simply be ignored, but instead should be recognized as technical and policy challenges that need to be addressed.
This paper provides a conceptual discussion of the level of knowledge needed to apply HT/HC methods for the purposes of (1) prioritization, (2) screening, and (3) hazard prediction. We then suggest frameworks for validation that should be considered to address the challenges noted above. The purpose is to provide foodfor-thought with the goal of stimulating further scientific dialog on this important topic (Stephens et al., 2011 (Stephens et al., , 2013 Judson et al., in press ).
Anchoring HT/HC methods and prediction models to adverse effects/adverse responses
The vision of 21st century toxicity testing includes the concept of ''toxicity pathways '' (NRC, 2007) . These are cellular response pathways, that, when sufficiently perturbed, are expected to result in adverse health effects. An adverse effect is defined as ''a change in morphology, physiology, growth, development, reproduction, or life span of a cell or organism, system, or (sub)population that results in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress, or an increase in susceptibility to other influences'', as defined in a recent ILSI/HESI workshop (Keller et al., 2012) . In the vision presented by the NRC panel (NRC, 2007) , low exposures could cause small perturbations that do not lead to any alterations in normal biological functions whatsoever. Higher exposures could lead to adaptive responses, which do not necessarily compromise cellular or organ functions. However, with sufficiently large exposures, perturbations could be great enough to produce cellular injury and adverse effects (Slikker et al., 2004) . Ankley et al. (2010) broadened the scope of toxicity pathways to define the broader construct of adverse outcome pathway (AOP) as representing ''existing knowledge concerning the linkage between the molecular initiating event (MIE) and an adverse outcome at the individual or population level.'' As such, an AOP is intended to span multiple levels of biological organization, linking the initial point of chemical-biological interaction within an organism (the MIE) to the adverse outcome in an organism or population. Therefore an AOP links, or anchors, an MIE to an adverse outcome through a series of key events.
Replacing the term ''Molecular Initiating Event'' with ''Initial Molecular Event''
The term ''Molecular Initiating Event'' is problematic. Although a MIE may be the first biological response event in the pathway, it does not necessarily ''initiate'' a chain of events that automatically leads to adverse effects.
Even in the area of mutagenesis and carcinogenesis, the initiating event is fixation of a mutation in DNA, and not the initial molecular event of a chemical reacting with DNA or even adduct formation. Mutations are the result of improper DNA repair following a damage event and result in DNA base sequence changes (Gorbunova et al., 2007; Preston et al., 2010) . For a number of years, DNA damage/genotoxicity has been linked incorrectly in the minds of many to mutatagenesis; similarly, current thinking indicates that the occurrence of mutations is also less clearly associated with the induction of cancer than previously believed (USEPA, 2007; Weinberg, 2000, 2011) .
A mutation is a heritable change in the DNA base sequence likely resulting in a different gene product (USEPA, 2007) . Historically, the multistage model for cancer dose response became linked to the concept of cancer initiation and promotion-the first model stage was ''initiation, the second stage ''promotion'' and later stages ''progression.'' However, neither the multistage model nor the simplistic initiation-promotion concept of cancer formation conveys the current biological understanding of carcinogenesis where it has become clear that tumorigenesis involves ''multiple rate limiting steps'' Weinberg, 2000, 2011) .
This potential confusion between the overly simplistic, concept of ''initiation'' of cancer and a molecular ''initiating'' event is a reason for suggesting the term MIE be changed to initial molecular event (IME). By utilizing the term MIE, the implication is that the adverse effect is ''initiated'' by the MIE and inferred by the detection and measurement of the MIE. This implication creates an unfortunate opportunity for misunderstanding and misuse of the MIE within an AOP. For example, in cases where the initial event is receptor or protein binding, it would be incorrect to interpret this is the same as an initiating event in either mutagenesis or carcinogenesis.
There may be a small number of AOPs for which the initial event is a mutation. Notwithstanding, AOPs for other types of responses must include elements that address threshold dose and reversibility. Receptor binding of ligands is reversible and governed by the law of mass action-whereas a mutation in DNA cannot be reversed. Of course, it should be noted that many mutations are not stable and can be repaired by repair enzymes. Further, even in the case of suicide inactivation of an enzyme/protein, there are threshold doses below which no adverse responses are elicited (see for example Vandekar et al., 1971) even though reduction in the activity of the protein moiety can be measured. Thus, as noted, it would be preferable to replace the term MIE with the term Initial Molecular Event (IME), because, with the exception perhaps of site-of-contact toxicants (e.g., corrosives) the first event in an AOP does not trigger or ''initiate'' a pathological response. An IME should be considered as a necessary step, but not a sufficient one, in the process of the discontinuum from exposure to adverse outcome (see Fig. 1 ). Hence, we use IME throughout the remainder of this paper.
Challenges in defining and using adverse outcome pathways
The key difference between a toxicity pathway (TP) and an AOP is that a TP is a cellular response pathway whereas an AOP as defined by Ankley et al. (2010) represents a plausible set of connections leading from the IME to the adverse effect. The AOP is anchored by the IME and the adverse effect. The level or type of activity in a cellular response pathway is related to toxicity, but the mere measurement of any degree of activity in an AOP does not constitute adversity. For example, what is not yet established for AOPs is the magnitude, frequency and duration of change in activities that are necessary to produce adversity. Therefore, measurable changes in activity should not be misinterpreted as demonstrating a 1:1 relationship between the IME and an adverse effect.
As depicted in Fig. 1 , the reality is that there is an ''exposure-effect discontinuum.'' The AOP conceptual model ties together molecular events, cellular responses, organ effects and organism and population outcomes through a number of key events, where the IME is simply the first (or one of the first) stages of the pathway. Each key event is a necessary element of the MOA/AOP and empirically observable (USEPA, 2005; Boobis et al., 2009) . To make the linkage between the IME and the adverse effect, an inherent assumption to the AOP concept is that an exposure must be at a sufficiently high level and/or duration to exceed the adaptive response of an organism. Not all exposures will produce adverse effects, even when measurable responses are detected in early events in the pathway (Slikker et al., 2004) . Indeed, early key events are likely interactions with molecular targets or cellular pathways that fall within the spectrum of adaptive or homeostatic responses. Key events that occur at higher doses or later in time may represent reversible toxic effects or physiological repair mechanisms. At even higher doses or later times, these toxic effects become irreversible and represent a failure of homeostatic mechanisms and repair processes.
The transition from adaptive/homeostatic mechanisms to repair mechanisms represents one discontinuum; the transition from reparable damage to irreparable damage represents a second discontinuum ( Fig. 1) . The specific combination of the exposure level, duration of exposure, and homeostatic/repair capacity at which these transitions occur determines the transition thresholds (Julien et al., 2009 ) and variations in homeostatic/repair capacities account for variations in transition thresholds and indeed, the observed threshold for the apical effect. In general, small or transient variations in these capacities will be insignificant in determining transition thresholds; however, sufficiently large changes in key events will lead to these discontinuities, and these transitions likely involve large changes in more than one aspect of the MOA/AOP . Understanding dose-related events and dose-dependent transitions and the duration of Fig. 1 . Illustration of the exposure effect discontinuum within the AOP conceptual framework. The discontinuous relationship between exposure, response and adverse effects is characterized by overlaying the dose-response relationship upon the AOP framework. The ''discontinuous'' flow via along the AOP begins with an initial response, the initial molecular event (IME), then proceeds, if magnitude, frequency and duration of exposure are of sufficient degree at each key event in the AOP, from IME to cellular responses, from there to organ effects and from there to adverse effects. At lower doses, effects may be reversible and although responses may be observed at a particular stage of the AOP, the dose magnitude/frequency/duration can be too low to trigger transition to the next event in the AOP. (Note: as discussed in the text, although some use the term ''molecular initiating event,'' the term ''initial molecular event'' is preferred. changes at the biochemical, cellular, organ, organism, and population levels will lead to improvements in prediction models based on AOPs.
Conceptually, TPs and AOPs are in fact biological response pathways, and, in general, they are linked or identical to normal response pathways that maintain homeostasis and normal function in the face of both internal and external stressors. Toxicity can be thought of as failures of homeostasis and resulting maladaptive and biologically inappropriate activities in these response pathways-but toxicity is clearly not a perturbation within the range of normal homeostatic responses.
Additional events in these pathways may be measurable because they are represented by one or more biomarkers. The measurable events further along the pathway that lead to, and are experimentally or toxicologically associated with and necessary for the adverse outcome are also, by definition, key events-empirically measurable precursor steps and necessary elements of the AOP/MOA.
MOA differs from mechanism, in that the latter implies a more detailed understanding of the molecular basis of the toxic effect (Seed et al., 2005; USEPA, 2005) . As part of an MOA, key events need to be linked to the adverse outcome albeit without exhaustive detail (USEPA, 2005) . Knowledge of the MOA/AOP and relevant biological pathways (TPs) will be needed for interpretation of assay results. For example, one could consider the assay results as providing information on key events at different points along the pathway; upstream or proximal events might suffice for priority setting, and information about downstream events would be more closely related to the overall adverse outcome. Therefore, assay results reflecting both upstream and downstream events in the MOA/AOP would be critical to providing confidence in an evaluation, especially when used for hazard prediction to support a risk management action and not just for screening/ prioritization.
One of the most significant challenges facing development of AOPs is integration of toxicokinetics within the toxicodynamic portions of the AOP. Absorption, distribution, metabolism and excretion (ADME) determine the concentration of active molecule at the target site, and this target concentration is the key to understanding dose response at a molecular, cellular, organ system, or organismal level.
The dynamics of ADME can be complex. For example, some substances may be detoxified to inactive substrates by glucuronidation during first pass metabolism following oral exposure. For other substances, the parent compound may be inactive, but metabolism results in generation of an active metabolite, which can then interact with biological macromolecules. Until such time as AOPs include ADME components, confidence in the predictive value of AOPs for apical toxicity must be tempered.
3. Applying the IOM, 2010 strategy to develop scientific confidence in HT/HC assays and prediction models
Validation cannot be performed in vacuo but should consider both the biological context and intended purpose; consideration of both is critical to ensure appropriate interpretation and use of the data. To this end, the validation scheme outlined in the report from the Institute of Medicine, Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease (IOM, 2010) provides a useful framework for application to HT/HC methods ( Fig. 2A) . The three key steps for developing an evidentiary basis for the use of biomarkers, Analytical Validation, Qualification and Utilization (IOM, 2010) , can be adapted for HT/HC methods.
Building from IOM, 2010, three steps for validation are proposed:
Analytical Validation: considering the analytical performance of an assay; Qualification: an assessment of the association of the assay with an initial molecular event, key event or biomarker associated with the mode of action (MOA); and Utilization: a contextual and weight-of-evidence analysis of the specific and possibly quantitative use of the assay based on all available evidence.
Analytical validation
A key principle of science is replicability-that scientists working in other laboratories can subsequently and independently verify observations and quantitative results. Ideally, analytical validation would include an assessment of reproducibility with testing in multiple independent laboratories. However, if assays are proprietary or rely on unique robotics, this may create challenges for analytical validation. Nonetheless, to meet the goal of inter-laboratory validation, individual assays, using the proprietary construct, can be tested in different laboratories. It is important to think of this aspect of analytical validation as a challenge to be met rather than a problem to be ignored. For example, for robotic assays employing a proprietary construct in 1536 well format, the same assay could be run in a 96-well format in other labs to show the assay is valid, predicated on the assumption that the robotic 1536 well format would not significantly affect the assay. Further, the proprietary construct can be run in parallel with a non-proprietary assay that measures substantially the same endpoint(s).
Some have suggested that assessment of test reliability and reproducibility from a single laboratory can provisionally be acceptable for validation (Balls et al., 2006) , as long as this limitation is considered as part of a weight of evidence determination. However, such a situation is far from ideal. Instead, a heuristic performance standard approach could be employed for proprietary methods/prediction models. A set of reference chemicals could be established, including both positive and negative effectors for such cases. The positive effectors would possess a specified range of EC50s/potencies, while the reference set would also provide full coverage of the known applicability domains. For example, for estrogen and androgen receptor binding assays and transcriptional activation assays, ICCVAM (2003) provides minimum procedural standards and a standard list of compounds to be used for validation. For both proprietary and non-proprietary HT/HC estrogen and androgen receptor binding/transcriptional activation assays, this set of standard compounds could be used to demonstrate suitable assay performance as a validation exercise. A suitable subset could also be included as quality assurance standards with each set of test articles analyzed to ascertain and document acceptable performance of the run.
To demonstrate how this approach might be applied, we evaluated the HT/HC results reported by Judson et al. (2010) for ICCVAM reference compounds tested in five ToxCast™ Phase I assays: two androgen receptor (AR) binding assays and three AR transcriptional activation (TA) response assays (two agonism and one antagonism assays). ICCVAM (2003) recommended a total of 78 reference compounds for validating ER and AR binding assays and ER TA and AR TA assays, which included a minimum subset consisting of 75% ''positive'' and 25% ''negative'' substances to assure delineation of specificity and sensitivity. Of the ICCVAM minimum subset for validating AR binding and AR TA activity, only 9 have been evaluated by EPA in ToxCast™ Phase 1. One of these, methyltrienolone, was often used as a positive control in each run . Of the remaining eight, 5 were ICCVAM-designated positives and 3 ICCVAM-designated negatives for assessing AR binding. The ToxCast™ human AR binding assay (NVS_NR_hAR) results correctly classified 3 of 5 positive compounds and all 3 negative compounds (Table 1) . Interpretation here may be somewhat complicated because the human AR binding assay (NVS_NR_hAR) was derived from LNCaP cells which have a mutation in the ligand binding domain which makes the binding pocket larger and more flexible therefore, likely to lead to false positive results (Knudsen et al., 2011) . The ToxCast™ rat AR binding assay (NVS_NR_rAR) classified all 8 compounds as negative (Table 1) , including all 5 of the ICC-VAM-designated positive agents, suggesting that this assay might not be useful in a screen to identify compounds with true AR binding activity.
For validation of AR TA agonist activity, of the 8 ICCVAM designated compounds (7 designated by ICCVAM an negative, 1 as positive) evaluated in the ToxCast™ AR TA assays (NCGC_AR_Agonist and ATG_AR_TRANS), both assays correctly classified the seven negative compounds but did not identify the single positive compound, linuron (Table 2) . Again, interpretation may be limited because of the imbalance between positive and negative compounds tested for this endpoint. Furthermore, in the ToxCast™ AR TA assay for antagonist activity (NCGC_AR_Antagonist), of the 8 ICCVAM designated compounds, all 5 positive compounds and all 3 negative compounds were correctly classified (Table 3) suggesting a higher degree of scientific confidence in this assay.
It should be recognized that this example uses a very limited subset of reference compounds, only 8 of the minimum 78 compounds identified by ICCVAM recommended for use in validation of in vitro endocrine disruptor screening assays. Further, ICCVAM's conclusion of whether a substance is positive or negative for an endpoint for both binding and transcriptional activation, and including agonism and antagonism, is often based on only 1 or 2 previous test results. Nonetheless, this example provides a starting point for discussion on the analytical validity of an assay. For instance, inclusion of the rat AR binding assay (NVS_NR_rAR) may not add value to a set of HT/HC assays to be used for prioritization, screening, or hazard identification purposes if the assay does not identify true positives. Given the importance of establishing scientific confidence in HT/HC assays focusing on evaluating the potential endocrine activity of substances, at a minimum, before the ToxCast™ endocrine assays for estrogen and androgen activity are used for priority setting or screening, a much more complete set of ICCVAM-recommended substances should be evaluated and the results publicly disseminated. Furthermore, an assessment of the concordance of results from assays aimed at measuring the same fundamental events should also be considered. Disconcordant outcomes may provide insight as to what other factors are influencing the measured response in assay results expected to be similar. In Phase 2 of ToxCast (data not yet released), it appears EPA is running approximately 20 additional ICCVAM-recommended endocrine active substances. Analyses of these results will be an important addition to the existing limited data set, and will be critical in building the necessary scientific confidence in these methods for potential future applications in priority setting and screening.
Qualification
In every biological pathway that begins with an IME, each and every step will have a dose response (e.g., Ong et al., 2010) . Each subsequent step will likely depend on the response level and duration of the prior step and will likely be less sensitive to the IME than the prior step. This initial sensitivity to perturbation is the very essence of biological response and initial sensitivity of the pathway is an adaptive feature that provides the organism with information. Within each pathway, downstream homeostatic controls will tend to dampen and modulate the effect of initiating event as the system attempts to maintain the normal state.
Qualification is the assessment of the association of the assay with an IME, key event or biomarker associated with the mode of action whereby a substance can cause an adverse response. By anchoring the HT/HC methods to a biological response pathway, the health outcome of concern is linked to the initiating event-this is the basis of the MOA or AOP. However, the nature of the subsequent downstream events will likely tend to lessen and modulate the effect of the IME. Thus, a specific assay response level itself may not predict an adverse health outcome in vivo, depending on where the key event measured by the assay occurs within the AOP.
Qualification of the assay results would consider the context in which to interpret the generated data. A purely empirical prediction model using assay results is far from ideal (e.g., Thomas et al., 2012) . The overall interpretation would likely involve: (1) an assessment of how well the assay results represented changes in a biomarker and the key events with which the biomarker is associated; and (2) a validated prediction model that incorporates details of dosimetry, bioavailability, ADME, and other relevant factors. The data evaluation procedures should describe how assays that examine components of an AOP can be interpreted in a manner which enables inference of the toxicity processes of ultimate concern.
Dosimetry and ADME are vital to consider for Qualification of assay results. For example, Reif et al. (2010) examined the ToxCast™ results of 309 chemicals as a proof-of-concept exercise for use as a decision-support tool for the Endocrine Disruptor Screening Program. Using the ToxPi visualization tool (ibid), where the sum of responses for each group of assays that form a slice of the ''pie'' is normalized to the highest score of the set of chemicals tested, not to a fixed, external reference set of standards, Bisphenol-A (BPA) received the highest normalized score (1.0) on the estrogenicity component (6 assays) and a normalized score of 0.4 (37th of 309) on the XME/ADME component (36 assays). However, in vivo, following environmentally relevant oral exposures to BPA, appreciable concentrations of free BPA in blood or tissues do not occur because it is almost completely conjugated to glucuronide in first pass metabolism occurring in enterocytes and the liver (Willhite et al., 2008; Hengstler et al., 2011) . The glucuronidated Reference substances were those recommended by ICCVAM (2003) form of BPA is inactive in terms of binding to the estrogen receptor (Matthews et al., 2001) . Currently, none of the assays in the XME/ ADME component measure glucuronidation. Inclusion of an assay for glucuronidation of phenolic chemicals such as BPA would allow a better understanding of potential biological response or lack thereof for such substances because glucuronidated substances have much lower affinities for binding to ER or AR receptor sites, compared to parent compounds (Zhang et al., 1999) . At the present time, how this knowledge of glucuronidation, or for that matter how the XME/ADME component, would be used quantitatively for inferring in vivo mediated responses remains unclear. Such information could certainly be used qualitatively and in designing subsequent in vivo evaluations. Most of the assays in ToxCast™ lack metabolic activity, which creates significant challenges for predicting potential in vivo activities, since some substances require metabolic activation to form the toxic moiety, and for others, the parent compound is the active chemical, with metabolism resulting in inactivation. Indeed for some chemicals, both the parent compound and the metabolite(s) may contribute to the toxicity. While endpoints for ''estrogenicity'' in the ToxCast™ assays may be suitable at some point for priority setting for further evaluation, in the absence of additional data, they cannot be used to infer an outcome. Knowledge of the MOA, TP, AOP or biological response pathway that is represented by a given assay within an HT/HC suite and knowledge of human dosimetry (ADME) are both critical for Qualification of an assay, especially if the assay is used for purposes other than simple priority setting. In summary, to be able to use the assay results in context, one would wish to test two hypotheses during the process of method validation: (1) whether a chemical known to produce an adverse outcome also produces a change in relevant HT/HC biomarkers for the key events; and (2) whether the data from measurements of these biomarkers can be integrated into a model that predicts the biological response of interest and that includes appropriate evaluation or delineation of ADME. Addressing these two hypotheses is the essence of Qualification as defined in IOM (2010).
The degree of Qualification will depend on the intended purpose. For the purpose of prioritization in which the objective is to screen substances in order to select a subset for further evaluation, Qualification might be based on the observed assay results known to reflect the IME and the use of a relatively simple prediction model (e.g., Wetmore et al., 2011) . However, even this most simplistic use for priority setting may be problematic if ADME is not considered. If ADME is not included, substances requiring metabolic activation for effects could be overlooked and substances for which the active parent compound is rapidly metabolized to an inactive moiety could be mischaracterized. For hazard identification purposes, particularly those related to classification and labeling decisions, additional tests, even in vivo animal bioassays, would be required. Since it appears that many of the HT/HC test methods are focused on measuring early events in the AOP, such as the IME, these methods are currently most suitable for priority setting and not for hazard prediction.
Qualification to establish the applicability of the results for a specific use will require the determination of appropriate quantitative cut-off levels for designation of a substance as, for example, ''positive,'' ''negative'' or ''equivocal.'' Therefore, the prediction model used for a particular intended purpose will need to be developed and appropriately evaluated.
Utilization
The difference between Qualification and Utilization is the level of quantitative knowledge about the biological response pathway. Utilization requires both a contextual understanding of the assay and a weight-of-evidence analysis of the specific use of the assay, based on all available evidence, for use in making qualitative or quantitative predictions. For the Utilization of HT/HC data as the basis of hazard prediction, a quantitative relationship between the (1) HT/HC results, (2) at least one biomarker of effect, and (3) the apical adverse effect must be known with a defined and likely high level of correlation/association.
Much more additional research is needed to gain confidence in the use of HT/HC assays and batteries for predicting adverse effects. It would also be desirable to have measurable dose-related events at the assay/biochemical, cellular, organ, organismal, and population levels along with a biological understanding of the relationship of key events at these four levels (e.g., Akahori et al., 2008) . In addition, a validated dosimetry model to translate these results into projected human exposure levels is needed.
These dose-related events at multiple levels of biological organization would then become key events within the MOA or part of a well-documented AOP. Indeed, it is this knowledge of the MOA that will enable Utilization of the assay results with scientific confidence for hazard prediction.
As more knowledge of the MOA is gained, organization of this knowledge and the relevant assay results within an AOP framework will permit inclusion of other types of data such as non-HT/HC assay results, read-across, (Q)SAR or human or animal biomarkers (Doull et al., 2007; Sobus et al., 2011) . One fortunate consequence of attaining the level of knowledge of the MOA needed to interpret HT/HC data is that these data can in turn ameliorate knowledge of the MOA. Hence, the results of HT/HC assays can be used in an iterative fashion to advance the state of biological knowledge of the AOP, TP or MOA and to better understand the dose-response of the apical effect.
Applying the OECD, 2007 (Q)SAR Validation Strategy to Develop Scientific Confidence in HT/HC Assays and Prediction Models
Another validation approach that merits consideration is the OECD Validation Principles for (Q)SAR. This approach was designed to provide a framework for interpreting (Q)SAR information in the context of regulatory purposes, and the five principles offer a comparable and additional perspective of how to validate and interpret assays and data from emerging technologies (Worth et al., 2005; OECD, 2007) . HT/HC assays are similar to (Q)SAR models-both are used to develop predictions of the biological activity of a given chemical or set of chemicals.
To provide transparency and increase scientific confidence in the use of (Q)SAR methods, each method should provide information and documentation for the following five validation principles:
2. An unambiguous algorithm. 3. A defined domain of applicability. 4. Appropriate measures of goodness-of-fit, robustness and predictivity. 5. A mechanistic interpretation, if possible.
Prior to any application in either regulatory programs and/or product stewardship scenario, a key requirement will be adequate characterization of the method, whether (Q)SAR models or HT/HC assays, in terms of performance, domain and mechanistic relevance. Some of the (Q)SAR principles are more relevant to assay performance whereas others more relevant to the prediction model used to interpret the results.
(Q)SAR Principles 1 and 4 show parallels with ''Analytical Validation'' (Fig. 2) in terms of quantifying and characterizing the predictive performance of the assay itself-does the assay discriminate between activity/non-activity and/or potency? Indeed, the assessment of assay performance characteristics mirrors principle 4-''appropriate measures of goodness-of fit, robustness and predictivity''. This is no more than common sense; any assay method needs to have associated with it some measure of reliability, reproducibility and robustness for discriminating activity/inactivity as well as potency.
Principles 1 and 5 mirror ''Qualification'', assuring that there is a defined endpoint or key event for which data are being generated and that the assay fits in the context of the overall MOA or AOPthe assay must generate information pertinent to downstream events. Such mechanistic relevance is essential to provide the appropriate biological anchor within the framework of an MOA or AOP.
Finally, Principle 3 addresses the domain of applicability of the assay-in what circumstances or conditions, to what purpose, and for which chemicals, can the assay provide critical information to understand the degree of confidence one can assign to a particular interpretation of the data. It is also essential to appreciate the scope of the chemical landscape to which the assay is applicable. This will also be relevant for determining the applicability domain for a given MOA, TP or AOP and permit the development of toxicologically meaningful chemical categories.
Together these components are pertinent to help determine what decisions an individual assay and associated prediction model result can reliably support. Different purposes for assay results may allow different levels of uncertainty/confidence. As part of an overall strategy to address chemical hazard, (Q)SAR data need to be validated in a manner appropriate to their use (Eriksson et al., 2003) .
For example, the task of rank ordering and prioritizing chemicals for a subsequent and more detailed toxicity evaluation would conceivably permit a higher degree of uncertainty than would the use of results for hazard prediction and regulatory actions resulting in significant risk management actions. This difference is also mirrored in the (Q)SAR world in terms of whether all 5 principles are adequately addressed and the result of a given (Q)SAR can be used as the sole evaluation, or whether the results are sufficient only as supporting information in a weight of evidence approach (ECHA, 2008; Worth et al., 2007) .
With respect to HT/HC assays, these five principles could be readily adopted as a standard of practice. In which case developers of such methods would be expected to provide transparent documentation in the public domain regarding the extent to which a given method does, or does not, adhere to each of these principles. In this manner, those relying on the results of such methods would have a clearer understanding of the scientific applicability, limitations and robustness of a method.
Review, endorsement and communication of validation results
In addition to having confidence in the assay results and predictions, end users need to be able to access the information easily. Possibilities for achieving these aims include publication in the peer reviewed literature, evaluation by an independent science advisory board, or an approach similar to the Cochrane Collaboration that would provide systematic review of assay results and their use for specific purposes (Chalmers, 1993; Chalmers and Haynes, 1994) . This last possibility may suggest a role for the Evidence-Based Toxicology Collaboration Consortium (see ebtox.com for further information).
The path ahead
The difficulty with interpretation of in vitro and in silico toxicity evaluation is highlighted by Thomas et al. (2012) , in which the ToxCast™ Phase I data were evaluated comprehensively; the predictive performance of more than 600 in vitro assays was examined across 60 in vivo endpoints using 84 different statistical classification methods. In addition, the predictive power of these models was compared with that of QSAR and chemical descriptors. The predictive power of the in vitro assays was not significantly different than that of the chemical descriptors. Nonetheless, these authors and Judson et al. (2010) suggest that the assays can be viewed as a survey of IMEs, and that responses of some assays or combinations of assays can be viewed as positive or negative attributes for toxicity, and that it may be possible to use the combined net of such attributes for a given chemical for prioritizing chemicals for in vivo testing.
Some of the challenges with interpreting HT/HC methods for toxicity evaluations can be overcome by focused efforts to develop greater scientific confidence in the assays and their prediction models. The frameworks published by IOM (2010), Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease and the OECD Validation principles for (Q)SARs (OECD, 2007) provide appropriate contexts to assess the robustness, domain of applicability and utility of HT/HC assays and their generated data. These frameworks are flexible and can be aligned with the intended use(s) of the methods and prediction models. Heuristic performance standards are practical solutions to address the issue of cross-laboratory testing for proprietary HT/HC assays or those which may rely on specialized robotics. Knowledge of biological response pathways is a critical component in the validation and interpretation of HT/HC assays and their data. Anchoring the assays and their prediction models to specific MOAs and/or AOPs will be essential for the integration of HT/HC assay results into risk assessment and to ensure that the prediction models are both rigorous and fit for their intended purpose. The uptake and acceptance of HT/HC assays and prediction models depends in a large part on transparency, availability of data and thorough peer review of the assays and prediction models. Effective communication and dissemination of this information to end users are essential.
Using the IOM, 2007 framework as a lens for assessing the validation status of HT/HC assays indicates for many of the assays, the best that can be done is Analytical Validation. For other assays, those focused on specific purposes and known MOAs or well-defined AOPs, developing the datasets necessary for Qualification is achievable-many of the endpoints focus on measuring the IMEs or other early key events. Then the HT/HC assays/prediction models that meet the requirements of Qualification would be suitable for screening and prioritization. Although Qualification is insufficient for hazard prediction, this would still result in many benefits-by providing a biological basis for differentiating substances that warrant more in depth testing from those that do not.
For hazard characterization-the prediction of adverse effectsmuch more additional research is needed to develop the data sets and prediction models to meet the level of scientific confidence embodied in the concept of Utilization. This will require a better understanding to develop the quantitative relationship among the (1) HT/HC results, (2) biomarkers of effect, and (3) apical adverse effects. When asked about the number of toxicity pathways, Thomas Hartung opines ''as the number of cellular targets and metabolic pathways is finite, the number of PoT [Toxicity Pathways] should be, too. Evolution cannot have left too many Achilles heels given the number of chemicals surrounding us and the astonishingly large number of healthy years we enjoy on average'' (Hartung and McBride, 2011) . Although there are evolutionary and energy constraints on the complexity of human biology (Mayr, 1982) , the question of coverage by HT/HC batteries of the entire domain of toxicity pathways remains unknown and the question of whether these current HT/HC molecular screening programs represent a sufficient number of key components of pathways remains unanswered. The large number of assays within ToxCast™ (Phase 1, 467 assays as of December, 2009, see Judson et al., 2010) suggests a degree of confidence that a large range of AOPs/TPs are largely covered. However, much work is needed to align these ''parts'' with specific pathways. Moreover, as it exists today, the ToxCast™ battery contains a considerable amount of overlap in the genes/proteins that are measured. For example, there are 6 assays related to ERa: two competitive binding assays from Novascreen (1 human, 1 bovine), two Attagene multiple reporter transcription factor assays (1 cis and 1 trans), and two NCGC reporter gene assays (1 measuring agonist activity and 1 for antagonist activity) (Judson et al., 2010, supplementary material) . The contribution of such overlap in improving predictive models remains to be shown.
The activities of the Tox21 program, a collaboration of EPA, the Food and Drug Administration, the National Institutes of Environmental Health Sciences/National Toxicology Program, and the National Institutes of Health Chemical Genomics Center (http:// epa.gov/ncct/Tox21/) expand test methods, to increase the number of chemicals evaluated, to develop and evaluate new and improved prediction models, to collaborate and to publish in peer reviewed journals and EPA's leadership in disseminating data via the web 1 and through communities of practice 2 are commendable. This open exchange, coupled with the OECD work program for AOPs (OECD, 2011) and the International QSAR Foundation's development of Effectopedia 3 will enable HT/HC methods, AOPs and prediction models to be developed, evaluated, refined and updated as part of a global scientific community collaboration. As these activities proceed, application of the approaches discussed in this paper can be used to enhance scientific confidence in the assays and their prediction models. To move forward, several actions are recommended: (1) the MIE term should be replaced with IME; (2) drawing from the IOM methodology and/or the OECD QSAR principles, a specific validation strategy should be developed and implemented for HT/HC assays and their prediction models, focused on the specific biological response of interest and anchored to an adverse effect/response; (3) analytical validation of HT/HC estrogen and androgen assays should include all, or at least a substantial sub-set, of the ICCVAM recommended positive and negative reference compounds; and (4) to build scientific confidence, data should be publicly disseminated and assay results and prediction models should to be subjected to independent scientific peer review.
